Evidence Library
Filter by drug, type, year, and open access.
30 results
- Therapeutic Drug Monitoring in Psychiatry (Review) — Frontiers/PMC (2024)• Drug: ClozapineOpen accessPMCID
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a network meta-analysis. — The Lancet Psychiatry (2023)• Drug: LurasidoneDOIPMID
- Pharmacological treatment for bipolar mania: network meta-analysis of RCTs. — Molecular Psychiatry (2022)• Drug: QuetiapineOpen accessDOIPMIDPMCID
- Pharmacological treatments for antipsychotic-induced hyperprolactinemia: network meta-analysis. — Translational Psychiatry (2022)• Drug: RisperidoneOpen accessDOIPMIDPMCID
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. — CNS Drugs (2021)• Drug: PaliperidoneOpen accessDOIPMIDPMCID
- 6‑month paliperidone palmitate (PP6M): review — Review (2021)• Drug: Paliperidone
- Lurasidone in bipolar depression: meta‑analysis — Meta‑analysis (2020)• Drug: Lurasidone
- Efficacy of Quetiapine in Bipolar Depression: Meta‑analysis — Meta‑analysis (2020)• Drug: Quetiapine
- Comparative effects of 18 antipsychotics on metabolic function in schizophrenia: systematic review and network meta-analysis. — The Lancet Psychiatry (2020)• Drug: OlanzapineOpen accessDOIPMIDPMCID
- Carbamazepine‑induced hyponatremia: risk and management — Review (2019)• Drug: Carbamazepine
- Quetiapine in schizophrenia and bipolar disorder: systematic review — Systematic review (2019)• Drug: Quetiapine
- Metabolic effects of olanzapine: systematic review — Systematic review (2019)• Drug: Olanzapine
- Risperidone and prolactin: safety review — Review (2019)• Drug: Risperidone
- Haloperidol decanoate dosing and conversion: review — Review (2018)• Drug: Haloperidol
- Risperidone efficacy in schizophrenia: meta‑analysis — Meta‑analysis (2018)• Drug: Risperidone
- QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. — Psychosomatics (2018)• Drug: ZiprasidoneDOIPMID
- AGNP Consensus Guidelines for TDM in Psychiatry — Pharmacopsychiatry (2018)• Drug: ClozapineOpen access
- Paliperidone palmitate long‑acting injection: efficacy and safety (review) — Review (2018)• Drug: Paliperidone
- Valproate monitoring and safety: guideline/consensus — Guideline (2018)• Drug: Valproate
- CANMAT and ISBD 2018 guidelines for the management of patients with bipolar disorder. — Bipolar Disorders (2018)• Drug: ValproateOpen accessDOIPMIDPMCID
- Ziprasidone and QTc prolongation: review — Review (2017)• Drug: Ziprasidone
- Paliperidone palmitate vs oral antipsychotics: comparative effectiveness — Observational (2017)• Drug: Paliperidone
- Olanzapine/fluoxetine for bipolar depression: randomized trials — RCTs (2016)• Drug: Olanzapine
- Establishing a dose–response relationship for haloperidol decanoate — Psychiatric Bulletin (2005)• Drug: HaloperidolDOI
- Haloperidol serum concentrations and D2 receptor occupancy during low‑dose treatment with haloperidol decanoate — International Clinical Psychopharmacology (1997)• Drug: HaloperidolDOI
- Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate — Progress in Neuro‑Psychopharmacology and Biological Psychiatry (1996)• Drug: HaloperidolDOI
- Disposition of haloperidol and reduced haloperidol plasma levels after single‑dose haloperidol decanoate administration — Human Psychopharmacology: Clinical and Experimental (1995)• Drug: HaloperidolDOI
- D2 dopamine receptor occupancy during low‑dose treatment with haloperidol decanoate — American Journal of Psychiatry (1995)• Drug: HaloperidolDOI
- Review of carbamazepine-induced hyponatremia. — Progress in Neuro-Psychopharmacology & Biological Psychiatry (1994)• Drug: CarbamazepineDOIPMID
- Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics. — L'Encephale (1987)• Drug: HaloperidolPMID